Clinical Trials Browser

Phase 1/2 × berzosertib × 90 days × Clear all

NCT04802174 2026-03-17

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Phase 1/2 Active not recruiting

Small Cell Lung Carcinoma